Extended-release divalproex sodium for mood stabilization.

Study Objective: To evaluate the efficacy, safety, and tolerability of extended-release divalproex sodium.

Design: Prospective, open-label, 4-week study

Setting: Long-term care facility of the Missouri Department of Mental Health.

Patients: Ten hospitalized patients (mean age 39.

Adverse effects of atypical antipsychotic agents and their effects on quality of life.

Study Objectives: To determine how axis III metabolic disturbances associated with atypical antipsychotic agents (weight gain, diabetes mellitus, and hyperlipidemia) affect patients' quality of life by comparing perceived quality of life of patients taking these agents who developed the disorders with those who did not develop them. A secondary objective was to compare patients' assessments of their quality of life with assessments made of the same patients by their treating psychiatrists.

Design: Analysis of questionnaire results.

Seizures and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and clomipramine.

Seizure activity is a known complication associated with multiple sclerosis; however, it may also result from side effects of the treatments for the disease. A 21-year-old man with Tourette's syndrome, pedophilia, Asperger's syndrome, and multiple sclerosis experienced seizures after receiving therapy with interferon beta-1a. Adjustments in his drug regimen led to the discovery of pseudoparkinsonism and other extrapyramidal symptoms.